Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v3-EN
Language French English
Date Updated 2019-12-16 2019-12-16
Drug Identification Number 02221861 02221861
Brand name ANANDRON ANANDRON
Common or Proper name Anandron Anandron
Company Name CHEPLAPHARM ARZNEIMITTEL GMBH CHEPLAPHARM ARZNEIMITTEL GMBH
Ingredients NILUTAMIDE NILUTAMIDE
Strength(s) 50MG 50MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 90 90
ATC code L02BB L02BB
ATC description HORMONE ANTAGONISTS AND RELATED AGENTS HORMONE ANTAGONISTS AND RELATED AGENTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date
Actual start date 2019-11-19 2019-11-19
Estimated end date 2019-12-06 2019-12-06
Actual end date 2019-12-13 2019-12-13
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments Delay in Production - The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. Delay in Production - The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments